- Experience with the use of bortezomib (Velcade) in the Czech Republic since 20042011 | Faculty of Medicine in Hradec Králové
- The Proteasome Inhibitor Bortezhomib (Velcade) in the Treatment of Relapsed/Refracotry Multiple Myeloma: The First Experience in the Czech Republic2005 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezomib (Velcade) in he Treatment of Relapsed/Refractory Multiple Myeloma. The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3007Publication without faculty affiliation
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic2005 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezhomib (Velcade) in the Treatment of Relapsed/Refracotry Multiple Myeloma: The First Experience in the Czech Republic +12005 | Faculty of Medicine in Hradec Králové
- Efekt bortezomibu (Velcade) u mnohočetného myelomu.Souhrn výsledků po 20 měsících zkušeností v ČR +1Publication without faculty affiliation
- The first experience with bortezomib multiple myeloma therapy in Czech republic +1Publication without faculty affiliation
- The Proteasome Inhibitor Bortezomib (Velcade) in he Treatment of Relapsed/Refractory Multiple Myeloma. The First Experience in the Czech Republic +12005 | Faculty of Medicine in Hradec Králové
- Bortezomib (velcade) for refractory/relapsed multiple myeloma-results of Czech myeloma group (CMG) and Slovak myeloma society (SMS)Publication without faculty affiliation
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
